Saturday, August 2, 2025

Learn the doc – The New York Instances

Page 1 of 5

EUROPEAN COMMISSION

Brussels, 28.7.2025 C(2025) 5429 closing

Ms Stevis-Gridneff

DECISION OF THE EUROPEAN COMMISSION PURSUANT TO ARTICLE 11 OF THE DETAILED RULES FOR THE APPLICATION OF REGULATION (EC) No 1049/2001, ANNEXED TO THE RULES OF PROCEDURE OF THE COMMISSION¹

Topic: Your confirmatory software for entry to paperwork beneath Regulation (EC) No 1049/2001 – EASE 2022/2678

Expensive Ms Stevis-Gridneff,

I confer with your observe of 9 August 2022, registered on the identical day, by which you lodged a confirmatory software in accordance with Article 7(2) of Regulation (EC) No 1049/2001 relating to public entry to European Parliament, Council and Fee documents² (hereafter ‘Regulation (EC) No 1049/2001′).

1. CONTEXT ON THE PRESENT DECISION

1. In your preliminary software of 11 Might 2022, you requested entry to:

“All textual content messages between President Ursula von der Leyen and Albert Bourla, the chief govt of Pfizer, from January 1, 2021 to the current’.

2. By letter of 20 July 2021, the unit E.4 ‘Well being, Training & Tradition’ of the Secretariat- Common of the European Fee knowledgeable you that the European Fee doesn’t maintain any paperwork that will correspond to the outline offered in your software.

3. In your confirmatory software of 9 August 2022, you requested a evaluate of this place. You referred to the article entitled “How Europe Sealed a Pfizer Vaccine Deal With Texts and Calls”, printed on the New York Instances on 28 April 2021, which experiences that “for a month, Ms. von der Leyen had been exchanging texts and calls with Albert Bourla, the chief govt of Pfizer”.

1 Fee Choice (EU) 2024/3080 of 4 December 2024 establishing the Guidelines of Process of the Fee and amending Choice C(2000) (OJ L, 2024/3080, 5.12.2024,

http://knowledge.europa.eu/eli/dec/2024/3080/oj).

3614

ELI:

2 OJ L145, 31.05.2001, p. 43.

Fee européenne/Europese Commissie, 1049 Bruxelles/Brussel, BELGIQUE/BELGIË – Tel. +32 22991111

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles